Drugs / 212Pb-NG001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05725070 | Mar → Jul 2023 | prostate carcinoma | ARTBIO Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 212Pb-NG001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05725070 ↗ |
| Modality | Other / unclassified | “targeted alpha-emitting radiopharmaceutical” NCT05725070 ↗ |
| Route | Intravenous | “10 MBq dose IV” NCT05725070 ↗ |